All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
On the heels of a potential $1 billion oncology collaboration, Incyte Corp.'s JAK program snagged another partner, licensing oral JAK/JAK2 inhibitor INCB28050 to Eli Lilly and Co. in a potential $755 million deal that gives the biotech some big pharma muscle in the crowded rheumatoid arthritis space. (BioWorld Today)